Zacks Investment Research
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosSummit Therapeutics announced a clinical collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab in combination with Datroway across multiple solid tumors, starting with a phase III study in first-line triple-negative breast cancer. This partnership builds on AstraZeneca's $2 billion investment in Summit announced the previous week, expanding ivonescimab's development pipeline and creating additional clinical and commercial opportunities.
